Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald de Wit

Showing results (61-70 of 204) with videos related to

Pageof 21
Sort By:
Nature Communications|April 8, 2023
Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learningAnouk C de Jong, Alexandra Danyi, Job van Riet, et al.
Journal of Geriatric Oncology|February 6, 2014
Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trialAnne M Horgan, Bostjan Seruga, Greg R Pond, et al.
Cancer Treatment Reviews|May 19, 2015
Inter-patient variability in docetaxel pharmacokinetics: A reviewAnnemieke J M Nieuweboer, Ellen S de Morrée, Anne-Joy M de Graan, et al.
Cancer|June 24, 2005
Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trialsRichard J Gralla, Ronald de Wit, Jorn Herrstedt, et al.
Prostate Cancer and Prostatic Diseases|January 18, 2022
Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARDRonald de Wit, Stephen J Freedland, Stephane Oudard, et al.
Cancer|August 15, 2013
Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trialsMichael T Schweizer, Peng Huang, Michael W Kattan, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 2019
Impact of progression at baseline and on-treatment progression events in three large prostate cancer trialsDebbie G Robbrecht, Nicolas Delanoy, Ian F Tannock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986Maria De Santis, Joaquim Bellmunt, Graham Mead, et al.
European Urology Oncology|August 15, 2019
Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in SwedenTushar Srivastava, Vimalanand S Prabhu, Haojie Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2006
Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area valuesWalter J Loos, Felix E de Jongh, Alex Sparreboom, et al.
Pageof 21

Showing results (61-70 of 204) with videos related to

Sort By:
Pageof 21
Nature Communications|April 8, 2023
Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learningAnouk C de Jong, Alexandra Danyi, Job van Riet, et al.
Journal of Geriatric Oncology|February 6, 2014
Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trialAnne M Horgan, Bostjan Seruga, Greg R Pond, et al.
Cancer Treatment Reviews|May 19, 2015
Inter-patient variability in docetaxel pharmacokinetics: A reviewAnnemieke J M Nieuweboer, Ellen S de Morrée, Anne-Joy M de Graan, et al.
Cancer|June 24, 2005
Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trialsRichard J Gralla, Ronald de Wit, Jorn Herrstedt, et al.
Prostate Cancer and Prostatic Diseases|January 18, 2022
Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARDRonald de Wit, Stephen J Freedland, Stephane Oudard, et al.
Cancer|August 15, 2013
Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trialsMichael T Schweizer, Peng Huang, Michael W Kattan, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 2019
Impact of progression at baseline and on-treatment progression events in three large prostate cancer trialsDebbie G Robbrecht, Nicolas Delanoy, Ian F Tannock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986Maria De Santis, Joaquim Bellmunt, Graham Mead, et al.
European Urology Oncology|August 15, 2019
Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in SwedenTushar Srivastava, Vimalanand S Prabhu, Haojie Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2006
Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area valuesWalter J Loos, Felix E de Jongh, Alex Sparreboom, et al.
Pageof 21